Related Experiment Video
Updated: Jul 17, 2025
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
Effects of liraglutide on extraglycemic inflammatory markers and renal hemodynamic parameters in diabetic kidney
Wenjuan Song1, Mei Xu1, Xuemei Sun2
1Department of Endocrinology, People's Hospital of Chengyang District, Qingdao, China.
Insights
Liraglutide treatment in early diabetic kidney disease (DKD) patients significantly reduced inflammatory markers and improved renal function indicators. This study highlights liraglutide
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Diabetic kidney disease (DKD) is a leading cause of chronic kidney disease globally.
- Liraglutide is a widely used medication for DKD, but its effects on inflammatory markers and renal hemodynamics require further investigation.
- Early detection and intervention are crucial for managing DKD progression.
Purpose of the Study:
- To evaluate the impact of liraglutide on extraglycemic inflammatory markers in early DKD patients.
- To assess the effects of liraglutide on renal hemodynamic parameters in early DKD.
- To compare the efficacy of liraglutide plus metformin versus metformin alone in managing early DKD.
Main Methods:
- A 3-month study involving 160 early DKD patients, divided into a control group (metformin) and a treatment group (liraglutide plus metformin).
- Measurements included urinary albumin-to-creatinine ratio (UACR), Doppler ultrasound for renal artery blood flow, and serum levels of inflammatory markers (CRP, TNF-α, IL-6) and cystatin.
- Body mass index (BMI), waist circumference (WC), and low-density lipoprotein cholesterol (LDL) were also monitored.
Main Results:
- The liraglutide group showed significant reductions in BMI, WC, and LDL compared to the control group.
- Urinary cystatin and UACR levels were significantly lower in the liraglutide group.
- Renal artery end-diastolic velocity (EDV) and peak systolic velocity (PSV) increased, while the resistance index (RI) decreased in the liraglutide group, indicating improved renal blood flow. Inflammatory markers (CRP, TNF-α, IL-6) were also reduced.
Conclusions:
- Liraglutide, in combination with metformin, effectively reduces inflammatory markers and improves renal hemodynamic parameters in early DKD patients.
- Liraglutide demonstrates beneficial effects beyond glycemic control in managing early diabetic kidney disease.
- These findings support the use of liraglutide as a therapeutic option for early DKD management.
Abstract:
Diabetic kidney disease (DKD) was the leading cause of kidney disease, which has been a crucial public health. Liraglutide is a drug, widely used for DKD treatment globally. However, the extraglycemic inflammatory markers and renal hemodynamic parameters of DKD patients treated with liraglutide has been not reported. In this study, 160 patients with early DKD were enrolled, 80 cases in the control group and 80 cases in the treatment group, respectively. The individuals in the control group were treated with metformin, while the individuals in the treatment group were treated with liraglutide and metformin for 3 months. The urinary microalbumin and urinary creatinine was measured to calculate the ratio (UACR), while the Doppler ultrasound were measured before and after treatment. After 3 months of treatment, body mass index (BMI), waist circumference (WC) and low-density lipoprotein cholesterol (LDL) in the treatment group were significantly decreased compared with before and after treatment in the control group; the levels of cystatin and UACR in treatment group were lower than before treatment and control group; The end-diastolic blood flow velocity (EDV) of renal artery and segment artery in treatment group was significantly higher than that before treatment and control group; The levels of CRP, TNF-α and IL-6 in the treatment group after treatment were lower than those before treatment and those in the control group. After 3 months of treatment, blood cystatin in the treatment group decreased significantly compared with before treatment and after treatment in the control group, with statistical significance After 3 months of treatment, the EDV of renal artery and renal segment in treatment group was significantly higher than that before treatment and control group, the peak systolic blood flow velocity (PSV) and EDV of renal interlobar artery in treatment group were significantly higher than those before treatment and control group. The resistance index (RI) was significantly lower than that before treatment and control group. Liraglutide can reduce inflammatory indicators, renal artery blood flow and renal function indicators in early DKD patients.
More Related Videos
04:14Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
Related Concept Videos
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
01:23Dipeptidyl Peptidase 4 Inhibitors
01:06Oral Hypoglycemic Agents: Glinides
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...